2014年5月12日 · In advanced urothelial cancer, treatment with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) results in a high response rate, less toxicity, and few dosing delays. We explored the efficacy and safety of neoadjuvant ddMVAC with pegfilgrastim support in muscle-invasive urothelial cancer (MIUC).

2022年3月9日 · 结果： 437 名患者（88%）接受了新辅助化疗；60% 的患者在 dd-MVAC 组中接受了计划的 6 个周期，84% 在 GC 组中接受了 4 个周期，之后分别有 91% 和 90% 的患者接受了手术。

2025年3月3日 · We herein report outcomes of dd-MVAC followed by switch maintenance avelumab in real-world patients with aUC for the first time. Avelumab therapy was significantly associated with longer survival in patients who achieved ≥ stable disease after first-line dd-MVAC.

2022年3月7日 · Recently, two phase II trials using dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) as NAC in MIBC reported promising results on local controls. 6, 7 We designed a randomized phase III controlled study comparing the efficacy of dd-MVAC or gemcitabine and cisplatin (GC) in patients for whom chemotherapy had been decided...

Platinum-based neoadjuvant chemotherapy (NCT) has been shown to improve survival outcomes in muscle-invasive bladder cancer (MIBC) patients, but the optimal neoadjuvant regimen has not been established. Methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) and gemcitabine and cisplatin/carbop …

2022年6月20日 · In the neoadjuvant group, PFS at 3 years was significantly higher in the dd-MVAC arm (66% v 56%, HR = 0.70 [95% CI, 0.51 to 0.96], P = .025). Conclusion: In the VESPER trial, dd-MVAC improved 3-years PFS over GC.

Dd-MVAC chemotherapy consisted of methotrexate (MTX) 30 mg/m2, vinblastine (VBL) 3mg/m2, adriamycin (ADM) 30 mg/m2 and cisplatin (CDDP) 70 mg/m2, administered in cycles of 14 days. Classic MVAC was a 4-week-per-cycle regimen which was also the combination of MTX 30 mg/m2, VBL 3 mg/m2, ADM 30 mg/m2 and CDDP 70 mg/m2.

4 个周期 dd-MVAC 的新辅助化疗是一种有效的治疗方案，具有较高的病理完全缓解率和降期以及可接受的毒性特征。 对于临床表现良好的患者，DD-MVAC 应被视为顺铂和吉西他滨的替代药物。

2022年3月11日 · GETUG-AFU V05 VESPER研究是膀胱癌围术期治疗发展20多年以来，第一个头对头比较GC和ddMVAC（剂量密集甲氨蝶呤＋长春碱＋多柔比星＋顺铂）用于MIBC新辅助治疗的Ⅲ期临床试验。 近日，JCO杂志在线发表了该研究随访40个月的结果。 根治性膀胱切除术仍然是非转移性MIBC局部治疗的金标准，采用新辅助化疗可带来5%的OS绝对获益，但最佳的NAC方案仍有待讨论。 已有Ⅱ期试验证实，ddMVAC新辅助治疗具有良好的耐受性，且可带来显著的 …

2024年1月22日 · 该研究旨在比较密集型甲氨蝶呤、长春碱、多柔比星和顺铂(dd-MVAC)与吉西他滨和顺铂(GC)在肌层浸润性膀胱癌患者围手术期化疗中的疗效，该研究支持dd-MVAC方案作为新辅助化疗。